Answers are grounded in this paper and cite their sources.
Review highlights adipose tissue's role in incretin-based drug effects on obesity, suggesting metabolic benefits.
Purpose of the Review This review summarizes recent evidence highlighting the specific role of adipose tissue in the systemic effects of incretin agonist-based drugs used in the treatment of obesity. Recent Findings The development of incretin agonist-based drugs has achieved unprecedented success in the pharmacological treatment of obesity and the improvement of obesity-related comorbidities. While initially shown to significantly reduce adipose tissue through decreased food intake, incretin-based therapy is also increasingly reported to alter the properties of adipose tissue. Recent experimental and human studies indicate that these anti-obesity drugs induce significant changes in the metabolism and inflammatory state of adipose tissue, while also promoting its thermogenic plasticity. Summary The direct and indirect actions of incretin-based anti-obesity drugs, which modify the properties of adipose tissue, are emerging as key contributors to the systemic health benefits of these treatments.
No takes yet. Share an insight, caveat, or question.
Villarroya et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: